Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nls Pharmaceutics Ltd (NLSP)

Nls Pharmaceutics Ltd (NLSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,979
  • Shares Outstanding, K 11,779
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,860 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NLSP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +20.64%
on 08/20/21
3.10 -15.16%
on 08/19/21
+0.29 (+12.39%)
since 08/17/21
3-Month
2.18 +20.64%
on 08/20/21
3.72 -29.30%
on 07/15/21
-0.46 (-14.89%)
since 06/17/21

Most Recent Stories

More News
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation

STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
New Strong Sell Stocks for July 30th

AEVA, FTS, GOL, NLSP and PCH have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2021.

GOL : 7.32 (-3.68%)
PCH : 53.02 (+1.80%)
FTS : 45.06 (-1.51%)
NLSP : 2.63 (-4.01%)
AEVA : 9.56 (-1.44%)
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer

STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy

Planned Phase 2a clinical trial anticipated to commence in August 2021

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th

STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...

NLSP : 2.63 (-4.01%)
NLSPW : 0.9105 (+0.04%)
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

an investor conference themed around investor education and advocacy begins next week, July 13 - 15, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period...

ACOG.VN : 1.770 (unch)
ACER : 2.46 (-0.40%)
ADXN : 9.24 (-4.54%)
AGRX : 1.0800 (+4.85%)
ATGN : 1.9600 (+4.26%)
ABIO : 3.10 (+1.64%)
AUUD : 2.69 (-14.33%)
BASA : 0.3299 (-0.03%)
BMRA : 4.65 (+10.71%)
BKTI : 2.99 (+2.40%)
BSFC : 6.4000 (+2.56%)
DTST : 5.27 (+0.76%)
DCTH : 9.12 (+0.44%)
DMIFF : 0.2200 (-4.35%)
DLPN : 12.36 (-0.56%)
FLUX : 6.38 (-4.63%)
GBNH : 8.85 (+0.57%)
HAVLF : 0.2275 (-0.57%)
ISDR : 27.17 (+3.01%)
INLB : 1.5800 (-6.51%)
KNWN : 2.4300 (+2.10%)
LXXGF : 0.3900 (-0.76%)
MKTY : 8.83 (+1.38%)
MMATF : 13.6500 (-2.15%)
MRVFF : 1.0500 (-2.78%)
NEPH : 9.03 (+0.67%)
NMTC : 4.05 (-7.74%)
NLSP : 2.63 (-4.01%)
OBLG : 2.50 (-0.79%)
PBLA : 2.16 (-6.09%)
POSAF : 1.0200 (+2.33%)
PCSA : 7.91 (+0.89%)
PTIX : 1.9200 (-1.03%)
QOEG : 0.1000 (+58.73%)
QIPT : 5.78 (-3.02%)
SNGX : 1.0800 (+1.89%)
STRR : 2.67 (-0.37%)
TGCB : 0.7500 (unch)
VERB : 1.9100 (+1.60%)
WTEQ.CN : 0.120 (unch)
WINT : 1.8900 (+3.85%)
AYRO : 3.64 (unch)
BCTX : 7.86 (+3.97%)
BTX : 11.95 (-3.40%)
HWAL : 1.7500 (-2.78%)
NMRD : 6.88 (+3.46%)
THBRF : 3.5000 (-3.05%)
TRIQ : 0.9999 (+11.10%)
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified...

ACOG.VN : 1.770 (unch)
ACER : 2.46 (-0.40%)
ADXN : 9.24 (-4.54%)
AGRX : 1.0800 (+4.85%)
ATGN : 1.9600 (+4.26%)
ABIO : 3.10 (+1.64%)
AUUD : 2.69 (-14.33%)
BASA : 0.3299 (-0.03%)
BKTI : 2.99 (+2.40%)
BSFC : 6.4000 (+2.56%)
DTST : 5.27 (+0.76%)
DCTH : 9.12 (+0.44%)
DMIFF : 0.2200 (-4.35%)
DLPN : 12.36 (-0.56%)
FLUX : 6.38 (-4.63%)
GBNH : 8.85 (+0.57%)
HAVLF : 0.2275 (-0.57%)
ISDR : 27.17 (+3.01%)
INLB : 1.5800 (-6.51%)
KNWN : 2.4300 (+2.10%)
LXXGF : 0.3900 (-0.76%)
MKTY : 8.83 (+1.38%)
MMATF : 13.6500 (-2.15%)
MRVFF : 1.0500 (-2.78%)
NEPH : 9.03 (+0.67%)
NMTC : 4.05 (-7.74%)
NLSP : 2.63 (-4.01%)
OBLG : 2.50 (-0.79%)
PBLA : 2.16 (-6.09%)
POSAF : 1.0200 (+2.33%)
PCSA : 7.91 (+0.89%)
PTIX : 1.9200 (-1.03%)
QOEG : 0.1000 (+58.73%)
QIPT : 5.78 (-3.02%)
SNGX : 1.0800 (+1.89%)
STRR : 2.67 (-0.37%)
TGCB : 0.7500 (unch)
VERB : 1.9100 (+1.60%)
WTEQ.CN : 0.120 (unch)
WINT : 1.8900 (+3.85%)

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 2.77
2nd Resistance Point 2.73
1st Resistance Point 2.68
Last Price 2.63
1st Support Level 2.59
2nd Support Level 2.55
3rd Support Level 2.50

See More

52-Week High 7.35
Fibonacci 61.8% 5.33
Fibonacci 50% 4.70
Fibonacci 38.2% 4.08
Last Price 2.63
52-Week Low 2.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar